My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

125.02 -0.18 (-0.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

67 68 Next >

Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024 ↗

January 22, 2024

Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.

Via Talk Markets

Why Gilead Sciences Stock Got Mashed on Monday ↗

January 22, 2024

A late-stage trial of an otherwise successful cancer drug failed to produce the desired results.

Via The Motley Fool

S&P 500, Dow Extend All-Time Highs: 'It's A Lot Of Fun For Stock Investors While It Lasts,' Wall Street Veteran Says ↗

January 22, 2024

Stock market continues upward trend, with all major indexes reaching record highs. Wall Street veteran Ed Yardeni outlines three possible scenarios.

Via Benzinga

Topics Stocks

Dow Gains Over 100 Points; Archer-Daniels-Midland Shares Plunge ↗

January 22, 2024

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.27% to 37,967.81 while the NASDAQ rose 0.31% to 15,358.70. The...

Via Benzinga

Topics Stocks

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

January 12, 2024

Via Benzinga

NASDAQ:GILD is probably undervalued for the fundamentals it is displaying. ↗

January 04, 2024

GILEAD SCIENCES INC (NASDAQ:GILD) is an undervalued gem with solid fundamentals.

Via Chartmill

(GILD) - Analyzing Gilead Sciences's Short Interest ↗

January 03, 2024

Via Benzinga

S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday? ↗

January 22, 2024

US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,...

Via Benzinga

Topics Stocks

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 22, 2024

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the...

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,100 Today ↗

December 25, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 22, 2024

Via Benzinga

Crude Oil Surges Over 2%; US Leading Economic Index Falls In December ↗

January 22, 2024

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Monday. The Dow traded up 0.41% to 38,018.23 while the NASDAQ rose 0.30% to 15,356.67. The S&P...

Via Benzinga

Topics Stocks

Why Is HIV Drug Giant Gilead Stock Falling Monday? ↗

January 22, 2024

Gilead's Phase 3 EVOKE-01 study on Trodelvy in metastatic non-small cell lung cancer didn't meet overall survival endpoint. Despite numerical OS improvement, further exploration is planned.

Via Benzinga

Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test ↗

January 22, 2024

The company had hoped Trodelvy would extend overall survival for patients with a form of lung cancer.

Via Investor's Business Daily

Gilead Provides Update on Phase 3 EVOKE-01 Study

January 22, 2024

From Gilead Sciences, Inc.

Via Business Wire

A Look Into Gilead Sciences Inc's Price Over Earnings ↗

December 22, 2023

Via Benzinga

EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker ↗

January 18, 2024

The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says.

Via Benzinga

AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades' ↗

January 18, 2024

On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc.

Via Benzinga

AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains ↗

January 11, 2024

AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.

Via Benzinga

Gilead’s Quiet Revolution: Is GILD the Next Big Stock to Soar? ↗

January 10, 2024

While Wall Street obsesses over weight-loss drugs, Gilead Sciences is working on life-saving treatments and GILD stock looks ready to rally.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 10, 2024

Via Benzinga

3 health care stocks off to strong starts in 2024

January 10, 2024

With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.

Via MarketBeat

Topics Artificial Intelligence

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 08, 2024

Via Benzinga

Nasdaq 100 Snaps Longest Negative Streak In 14 Months As Tech Stocks Find Relief On Mixed Data ↗

January 05, 2024

The Nasdaq 100 ended the first week of 2024 on a positive note, ending a five-session losing streak, despite volatile trading and conflicting economic data.

Via Benzinga

Will the Biotech sector sustain its momentum in 2024?

January 04, 2024

The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.

Via MarketBeat

Topics ETFs

This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns ↗

January 03, 2024

BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely...

Via Benzinga

Nasdaq 100 Alert: 7 Undervalued Tech Stocks Ready to Rocket in 2024 ↗

January 03, 2024

Despite the gains of last year there are still many undervalued tech stocks on the Nasdaq 100 waiting to explode higher in 2024

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

The 500 Top Stocks to Buy for 2024, Ranked by AI ↗

December 29, 2023

These are the very best stocks to buy for 2024 for any investor, according to Tom Yeung's MarketMasterAI system.

Via InvestorPlace

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

December 22, 2023

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.

Via Benzinga

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

67 68 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition